<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35421740</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-4758</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>104</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>The International journal on drug policy</Title>
          <ISOAbbreviation>Int J Drug Policy</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The introduction of fentanyl on the US-Mexico border: An ethnographic account triangulated with drug checking data from Tijuana.</ArticleTitle>
        <Pagination>
          <StartPage>103678</StartPage>
          <MedlinePgn>103678</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.drugpo.2022.103678</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0955-3959(22)00098-6</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Illicitly-manufactured fentanyls (fentanyl) have changed the risk environment of people who use drugs (PWUD). In California and many western US states, the opioid overdose rate spiked from 2016 to 2021, driven largely by fentanyl. Mexican border cities act as transit through-points for the illicit drug supply and similar evolving health risks are likely to be present. Nevertheless, due to data gaps in surveillance infrastructure, little is known about fentanyl prevalence in Mexico.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">We employ intensive ethnographic participant-observation among PWUD, as well as key informants including harm reduction professionals, EMTs, and physicians on the front lines in Tijuana, Mexico. We triangulate interview data and direct observations of consumption practices with n=652 immunoassay-based fentanyl tests of drug paraphernalia from mobile harm reduction clinics in various points throughout the city.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">PWUD informants described a sharp increase in the psychoactive potency and availability of powder heroin-referred to as "china white"-and concomitant increases in frequency of overdose, soft tissue infection, and polysubstance methamphetamine use. Fentanyl positivity was found among 52.8% (95%CI: 48.9-56.6%) of syringes collected at harm reduction spaces, and varied strongly across sites, from 2.7% (0.0-5.7%) to 76.5% (68.2-84.7%), implying strong market heterogeneity. Controlling for location of collection, syringe-based fentanyl positivity increased by 21.7% (10.1-42.3%) during eight months of testing. Key informants confirm numerous increased public health risks from fentanyl and describe the absence of a systematic or evidence-based governmental response; naloxone remains difficult to access and recent austerity measures have cut funding for harm reduction in Mexico.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Fentanyl, linked to powder heroin, is changing the risk environment of PWUD on the US-Mexico border. Improved surveillance is needed to track the evolving street drug supply in Mexico and related health impacts for vulnerable populations. Structural factors limiting access to naloxone, harm reduction, substance use treatment, and healthcare, and minimal overdose surveillance, must be improved to provide an effective systemic response.</AbstractText>
          <CopyrightInformation>Copyright © 2022 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Friedman</LastName>
            <ForeName>Joseph</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Social Medicine and Humanities, University of California, Los Angeles, CA, United States; Medical Informatics Home Area, University of California, Los Angeles, CA, United States. Electronic address: joseph.robert.friedman@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bourgois</LastName>
            <ForeName>Philippe</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Social Medicine and Humanities, University of California, Los Angeles, CA, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Godvin</LastName>
            <ForeName>Morgan</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>School of Public Health, Oregon Health Sciences University-Portland State University, Portland, OR, United States; Health in Justice Action Lab, Northeastern University, Boston, MA, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chavez</LastName>
            <ForeName>Alfonso</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Prevencasa, A.C, Tijuana, Baja California, Mexico.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pacheco</LastName>
            <ForeName>Lilia</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Prevencasa, A.C, Tijuana, Baja California, Mexico; Universidad Xochicalco, Facultad de Nutrición, Campus Tijuana, Mexico.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Segovia</LastName>
            <ForeName>Luis A</ForeName>
            <Initials>LA</Initials>
            <AffiliationInfo>
              <Affiliation>Prevencasa, A.C, Tijuana, Baja California, Mexico.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Beletsky</LastName>
            <ForeName>Leo</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Health in Justice Action Lab, Northeastern University, Boston, MA, United States; School of Law Northeastern University, Boston, MA, United States; Department of Health Sciences, Northeastern University, Boston, MA, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Arredondo</LastName>
            <ForeName>Jaime</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Canadian Institute for Substance Use Research (CISUR), Victoria, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>T32 GM008042</GrantID>
            <Acronym>GM</Acronym>
            <Agency>NIGMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Int J Drug Policy</MedlineTA>
        <NlmUniqueID>9014759</NlmUniqueID>
        <ISSNLinking>0955-3959</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000701">Analgesics, Opioid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013287">Illicit Drugs</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011208">Powders</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>36B82AMQ7N</RegistryNumber>
          <NameOfSubstance UI="D009270">Naloxone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>70D95007SX</RegistryNumber>
          <NameOfSubstance UI="D003932">Heroin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>UF599785JZ</RegistryNumber>
          <NameOfSubstance UI="D005283">Fentanyl</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000701" MajorTopicYN="N">Analgesics, Opioid</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D062787" MajorTopicYN="Y">Drug Overdose</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005283" MajorTopicYN="N">Fentanyl</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003932" MajorTopicYN="N">Heroin</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013287" MajorTopicYN="Y">Illicit Drugs</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008800" MajorTopicYN="N" Type="Geographic">Mexico</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009270" MajorTopicYN="N">Naloxone</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011208" MajorTopicYN="N">Powders</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Drug Checking</Keyword>
        <Keyword MajorTopicYN="N">Epidemiology</Keyword>
        <Keyword MajorTopicYN="N">Ethnography</Keyword>
        <Keyword MajorTopicYN="N">Fentanyl</Keyword>
        <Keyword MajorTopicYN="N">Mixed methods</Keyword>
        <Keyword MajorTopicYN="N">US-Mexico Border</Keyword>
      </KeywordList>
      <CoiStatement>Declarations of Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>14</Day>
          <Hour>20</Hour>
          <Minute>14</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35421740</ArticleId>
        <ArticleId IdType="doi">10.1016/j.drugpo.2022.103678</ArticleId>
        <ArticleId IdType="pii">S0955-3959(22)00098-6</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
